Balkrishna Acharya, Solleti Siva Kumar, Singh Hoshiyar, Singh Rani, Sharma Niti, Varshney Anurag
Drug Discovery and Development Division, Patanjali Research Institute, Haridwar, Uttarakhand, India.
Department of Allied and Applied Sciences, University of Patanjali, Patanjali Yog Peeth, Haridwar, Uttarakhand, India.
J Inflamm Res. 2021 Sep 17;14:4743-4760. doi: 10.2147/JIR.S313955. eCollection 2021.
Asthma is a heterogeneous airway inflammatory disease with limited therapeutic options. Traditional medicine is extensively used for treating various ailments including asthma. (SPAB) is a biotite-calx based Indian medicine.
We have tested for the anti-inflammatory and anti-asthmatic properties of SPAB, using a mouse model of ovalbumin-induced allergic asthma in-vivo and cell-based assays in-vitro. Histological analysis, qPCR and ELISA were performed to assess the pathology. SEM, EDX and XRD-analysis were performed to characterize the SPAB particles.
SEM, EDX and XRD-analysis identified the presence of SPAB particle of 100 nm-~1µm diameter and contains annite-1M, aluminium silicate, kyanite, aluminium oxide, magnesium silicate, and maghemite in the samples. Ova-challenge resulted in severe inflammatory responses, airway remodelling and increased oxidative burden in lungs. Importantly, prophylactic treatment with SPAB significantly attenuated allergen induced leukocyte infiltration specifically eosinophils, lymphocytes, macrophages and neutrophils in BALF. Ova-induced mucus hypersecretion, peri-bronchial collagen deposition, inflammatory cell infiltration and bronchial epithelial thickening were significantly abrogated upon SPAB treatment. qPCR and ELISA analysis identified that allergen induced increases in and cytokines mRNA in whole lungs and the levels of IL-6, IL-1β and TNF-α proteins in BALF were significantly attenuated upon oral SPAB treatment. SPAB restored allergen induced decreases in anti-oxidant markers in lungs. In-vitro, SPAB attenuated the secretion of IL-6, and TNF-α from human bronchial epithelial cells and modestly inhibited NF-kB/AP-1 pathway in HEK cells.
Taken together, our results experimentally validated the prophylactic ameliorative potential of the Indian classical medicine against asthma associated airway inflammation.
哮喘是一种异质性气道炎症性疾病，治疗选择有限。传统医学被广泛用于治疗包括哮喘在内的各种疾病。（SPAB）是一种基于黑云母 - 钙的印度药物。
我们使用卵清蛋白诱导的过敏性哮喘小鼠体内模型和体外细胞实验，测试了SPAB的抗炎和抗哮喘特性。进行组织学分析、qPCR和ELISA以评估病理情况。进行扫描电子显微镜（SEM）、能量散射X射线光谱（EDX）和X射线衍射（XRD）分析以表征SPAB颗粒。
SEM、EDX和XRD分析确定样品中存在直径为100nm至约1μm的SPAB颗粒，并且含有铁云母 - 1M、硅酸铝、蓝晶石、氧化铝、硅酸镁和磁赤铁矿。卵清蛋白激发导致严重的炎症反应、气道重塑和肺部氧化负担增加。重要的是，用SPAB进行预防性治疗可显著减轻变应原诱导的白细胞浸润，特别是支气管肺泡灌洗液（BALF）中的嗜酸性粒细胞、淋巴细胞、巨噬细胞和中性粒细胞。SPAB治疗后，卵清蛋白诱导的黏液高分泌、支气管周围胶原沉积、炎症细胞浸润和支气管上皮增厚均得到显著改善。qPCR和ELISA分析表明，口服SPAB治疗后，变应原诱导的全肺中 和 细胞因子mRNA增加以及BALF中IL - 6、IL - 1β和TNF - α蛋白水平显著降低。SPAB恢复了变应原诱导的肺中抗氧化标志物的降低。在体外，SPAB减弱了人支气管上皮细胞中IL - 6和TNF - α的分泌，并适度抑制了人胚肾（HEK）细胞中的核因子 - κB/激活蛋白 - 1（NF - kB/AP - 1）途径。
综上所述，我们的结果通过实验验证了这种印度古典药物对哮喘相关气道炎症的预防性改善潜力。
